Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Nature Medicine
|
February 28, 2012
NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses
Andrew Zloza, Frederick J Kohlhapp, Gretchen E Lyons, et al.
Journal for Immunotherapy of Cancer
|
May 21, 2015
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade
Frederick J Kohlhapp, Joseph R Broucek, Tasha Hughes, et al.
Oncogene
|
April 7, 2018
Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer
Jenna H Newman, David J Augeri, Rachel NeMoyer, et al.
The Journal of Investigative Dermatology
|
March 30, 2023
A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study
Kevinn Eddy, Kajal Gupta, Jeffrey C Pelletier, et al.
Cancer Immunology, Immunotherapy : CII
|
November 29, 2022
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
Ann W Silk, Steven J O'Day, Howard L Kaufman, et al.
Science Translational Medicine
|
March 1, 2013
Mutant HSP70 reverses autoimmune depigmentation in vitiligo
Jeffrey A Mosenson, Andrew Zloza, John D Nieland, et al.
Journal for Immunotherapy of Cancer
|
July 11, 2023
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
Sachin R Jhawar, Shang-Jui Wang, Aditya Thandoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2017
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Mark N Stein, Joseph R Bertino, Howard L Kaufman, et al.
Cell Reports
|
October 21, 2016
Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death
Frederick J Kohlhapp, Erica J Huelsmann, Andrew T Lacek, et al.
Journal for Immunotherapy of Cancer
|
May 24, 2019
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
Mark N Stein, Jyoti Malhotra, Rohinton S Tarapore, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Nature Medicine
|
February 28, 2012
NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses
Andrew Zloza, Frederick J Kohlhapp, Gretchen E Lyons, et al.
Journal for Immunotherapy of Cancer
|
May 21, 2015
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade
Frederick J Kohlhapp, Joseph R Broucek, Tasha Hughes, et al.
Oncogene
|
April 7, 2018
Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer
Jenna H Newman, David J Augeri, Rachel NeMoyer, et al.
The Journal of Investigative Dermatology
|
March 30, 2023
A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study
Kevinn Eddy, Kajal Gupta, Jeffrey C Pelletier, et al.
Cancer Immunology, Immunotherapy : CII
|
November 29, 2022
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
Ann W Silk, Steven J O'Day, Howard L Kaufman, et al.
Science Translational Medicine
|
March 1, 2013
Mutant HSP70 reverses autoimmune depigmentation in vitiligo
Jeffrey A Mosenson, Andrew Zloza, John D Nieland, et al.
Journal for Immunotherapy of Cancer
|
July 11, 2023
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
Sachin R Jhawar, Shang-Jui Wang, Aditya Thandoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2017
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Mark N Stein, Joseph R Bertino, Howard L Kaufman, et al.
Cell Reports
|
October 21, 2016
Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death
Frederick J Kohlhapp, Erica J Huelsmann, Andrew T Lacek, et al.
Journal for Immunotherapy of Cancer
|
May 24, 2019
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
Mark N Stein, Jyoti Malhotra, Rohinton S Tarapore, et al.
Page
of 8